• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

选择性雌激素受体下调剂的分子和结构决定因素的表征

Characterization of molecular and structural determinants of selective estrogen receptor downregulators.

作者信息

Fan Meiyun, Rickert Emily L, Chen Lei, Aftab Syed A, Nephew Kenneth P, Weatherman Ross V

机构信息

Department of Medical Sciences, Indiana University School of Medicine, Bloomington, IN, USA.

出版信息

Breast Cancer Res Treat. 2007 May;103(1):37-44. doi: 10.1007/s10549-006-9353-2. Epub 2006 Oct 11.

DOI:10.1007/s10549-006-9353-2
PMID:17033922
Abstract

Antiestrogens used for breast cancer therapy can be categorized into two classes that differ in their effect on estrogen receptor (ER) alpha stability. The selective estrogen receptor modulators (SERMs) stabilize ER alpha and the selective estrogen receptor downregulators (SERDs) cause a decrease in cellular ER alpha levels. A clinically relevant antiestrogen, GW7604, appears to work through a SERD-like mechanism, despite sharing the same molecular scaffold as 4-hydroxytamoxifen, a SERM. In order to investigate potential structural features of GW7604 responsible for SERD activity, GW7604 and two analogs were synthesized using a new, improved synthetic route and tested for their effects on ER alpha function and cell proliferation. The two analogs, which have an acrylamide or a methyl vinyl ketone replacing the acrylic acid group of GW7604, display lower binding affinity for ER alpha than GW7604, but show similar antagonism of estradiol-induced activation of ER alpha-mediated transcription as GW7604 and inhibit estradiol-induced proliferation of the MCF-7 cell line with a similar potency as GW7604. Unlike GW7604, neither analog has a significant effect on cellular ER alpha levels, suggesting that the carboxylate is a key determinant in GW7604 action and, for the first time, showing that this group is responsible for inducing ER alpha degradation in breast cancer cells.

摘要

用于乳腺癌治疗的抗雌激素药物可分为两类,它们对雌激素受体(ER)α稳定性的影响有所不同。选择性雌激素受体调节剂(SERM)可稳定ERα,而选择性雌激素受体下调剂(SERD)则会导致细胞内ERα水平降低。一种具有临床相关性的抗雌激素药物GW7604,尽管其与SERM 4-羟基他莫昔芬具有相同的分子骨架,但似乎是通过类似SERD的机制发挥作用。为了研究GW7604中负责SERD活性的潜在结构特征,采用一种新的改进合成路线合成了GW7604及其两种类似物,并测试了它们对ERα功能和细胞增殖的影响。这两种类似物分别用丙烯酰胺或甲基乙烯基酮取代了GW7604的丙烯酸基团,它们对ERα的结合亲和力低于GW7604,但与GW7604一样,对雌二醇诱导的ERα介导的转录激活具有类似的拮抗作用,并且以与GW7604相似的效力抑制雌二醇诱导的MCF-7细胞系增殖。与GW7604不同,这两种类似物对细胞内ERα水平均无显著影响,这表明羧酸盐是GW7604作用的关键决定因素,并且首次表明该基团负责诱导乳腺癌细胞中的ERα降解。

相似文献

1
Characterization of molecular and structural determinants of selective estrogen receptor downregulators.选择性雌激素受体下调剂的分子和结构决定因素的表征
Breast Cancer Res Treat. 2007 May;103(1):37-44. doi: 10.1007/s10549-006-9353-2. Epub 2006 Oct 11.
2
Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.一种与他莫昔芬相关的新型临床相关抗雌激素(GW7604)对雌激素受体α的分子作用机制
Endocrinology. 2001 Feb;142(2):838-46. doi: 10.1210/endo.142.2.7932.
3
Melatonin inhibits both ER alpha activation and breast cancer cell proliferation induced by a metalloestrogen, cadmium.褪黑素可抑制金属雌激素镉诱导的雌激素受体α激活及乳腺癌细胞增殖。
J Pineal Res. 2006 May;40(4):291-6. doi: 10.1111/j.1600-079X.2006.00315.x.
4
Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators.选择性雌激素受体下调剂之间功能上重要的机制差异的定义。
Cancer Res. 2007 Oct 1;67(19):9549-60. doi: 10.1158/0008-5472.CAN-07-1590.
5
The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells.他莫昔芬代谢产物内昔芬是一种强效抗雌激素,可靶向雌激素受体α,使其在乳腺癌细胞中降解。
Cancer Res. 2009 Mar 1;69(5):1722-7. doi: 10.1158/0008-5472.CAN-08-3933. Epub 2009 Feb 24.
6
Structural basis for an unexpected mode of SERM-mediated ER antagonism.选择性雌激素受体调节剂(SERM)介导的雌激素受体(ER)拮抗作用的意外模式的结构基础。
Mol Cell. 2005 May 13;18(4):413-24. doi: 10.1016/j.molcel.2005.04.014.
7
Anti-estrogenic effects of conjugated linoleic acid through modulation of estrogen receptor phosphorylation.共轭亚油酸通过调节雌激素受体磷酸化产生抗雌激素作用。
Breast Cancer Res Treat. 2005 Nov;94(2):161-9. doi: 10.1007/s10549-005-6942-4.
8
From ligand structure to biological activity: modified estratrienes and their estrogenic and antiestrogenic effects in MCF-7 cells.从配体结构到生物活性:修饰的雌三烯及其在MCF-7细胞中的雌激素和抗雌激素作用。
Steroids. 2004 Jun;69(6):401-18. doi: 10.1016/j.steroids.2004.03.014.
9
Selective estrogen-receptor modulators and antihormonal resistance in breast cancer.选择性雌激素受体调节剂与乳腺癌中的抗激素耐药性
J Clin Oncol. 2007 Dec 20;25(36):5815-24. doi: 10.1200/JCO.2007.11.3886. Epub 2007 Sep 24.
10
Troglitazone enhances tamoxifen-induced growth inhibitory activity of MCF-7 cells.曲格列酮增强他莫昔芬诱导的MCF-7细胞生长抑制活性。
Biochem Biophys Res Commun. 2008 Dec 5;377(1):242-7. doi: 10.1016/j.bbrc.2008.09.111. Epub 2008 Oct 7.

引用本文的文献

1
Interaction between Estrogen Receptors and p53: A Broader Role for Tamoxifen?雌激素受体与p53之间的相互作用:他莫昔芬的作用更广泛?
Endocrinology. 2025 Feb 5;166(3). doi: 10.1210/endocr/bqaf020.
2
Oestrogen receptor positive breast cancer and its embedded mechanism: breast cancer resistance to conventional drugs and related therapies, a review.雌激素受体阳性乳腺癌及其内在机制:乳腺癌对常规药物和相关疗法的耐药性,综述。
Open Biol. 2024 Jun;14(6):230272. doi: 10.1098/rsob.230272. Epub 2024 Jun 19.
3
Chemotherapy and Physical Therapeutics Modulate Antigens on Cancer Cells.
化疗和物理治疗调节癌细胞上的抗原。
Front Immunol. 2022 Jul 6;13:889950. doi: 10.3389/fimmu.2022.889950. eCollection 2022.
4
Heterodimeric GW7604 Derivatives: Modification of the Pharmacological Profile by Additional Interactions at the Coactivator Binding Site.异二聚体 GW7604 衍生物:通过在共激活剂结合位点的附加相互作用修饰药理学特性。
J Med Chem. 2021 May 13;64(9):5766-5786. doi: 10.1021/acs.jmedchem.0c02230. Epub 2021 Apr 27.
5
From Pure Antagonists to Pure Degraders of the Estrogen Receptor: Evolving Strategies for the Same Target.从雌激素受体的纯拮抗剂到纯降解剂:针对同一靶点的不断演进的策略。
ACS Omega. 2021 Mar 30;6(14):9334-9343. doi: 10.1021/acsomega.0c06362. eCollection 2021 Apr 13.
6
Recent progress in selective estrogen receptor downregulators (SERDs) for the treatment of breast cancer.用于治疗乳腺癌的选择性雌激素受体下调剂(SERDs)的最新进展。
RSC Med Chem. 2020 Mar 6;11(4):438-454. doi: 10.1039/c9md00570f. eCollection 2020 Apr 1.
7
Fulvestrant as a reference antiestrogen and estrogen receptor (ER) degrader in preclinical studies: treatment dosage, efficacy, and implications on development of new ER-targeting agents.氟维司群作为临床前研究中的参考抗雌激素和雌激素受体(ER)降解剂:治疗剂量、疗效及对新型ER靶向药物研发的影响
Transl Cancer Res. 2020 Aug;9(8):4464-4468. doi: 10.21037/tcr-20-2166.
8
Mechanisms of Breast Cancer in Shift Workers: DNA Methylation in Five Core Circadian Genes in Nurses Working Night Shifts.轮班工作者患乳腺癌的机制:夜班护士五个核心昼夜节律基因的DNA甲基化
J Cancer. 2017 Aug 24;8(15):2876-2884. doi: 10.7150/jca.21064. eCollection 2017.
9
A Review of Fulvestrant in Breast Cancer.氟维司群治疗乳腺癌的综述
Oncol Ther. 2017;5(1):17-29. doi: 10.1007/s40487-017-0046-2. Epub 2017 May 8.
10
Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.系统地对多靶点前列腺癌候选药物 galeterone 进行结构修饰,以产生新型的雄激素受体下调剂,作为治疗晚期前列腺癌的一种方法。
J Med Chem. 2013 Jun 27;56(12):4880-98. doi: 10.1021/jm400048v. Epub 2013 Jun 7.